Laura Melendez-Alafort

Dr. Laura Melendez-Alafort

Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128 Padua, Italy
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ABAlessandra Banzato
Alessandra Banzato
SBSara Bobisse
Sara Bobisse
MRMaria Rondina
Maria Rondina
DRDavide Renier
Davide Renier
FBFabio Bettella
Fabio Bettella
ARAntonio Rosato
Antonio Rosato
Purpose: This study was designed to evaluate the pharmacologic and biological properties of a paclitaxel-hyaluronan bioconjugate (ONCOFID-P) against IGROV-1 and OVCAR-3 human ovarian cancer xenografts following i.p. administration.

1 August 2003 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
Guillermina Ferro-FloresGuillermina Ferro-Flores
Guillermina Ferro-Flores
CMConsuelo Arteaga de Murphy
Consuelo Arteaga de Murphy
MPMartha Pedraza-López
Martha Pedraza-López
Laura Melendez-AlafortLaura Melendez-Alafort
Laura Melendez-Alafort
YZYu-Min Zhang
Yu-Min Zhang
DHDonald J Hnatowich
Donald J Hnatowich

1 April 2004 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
Laura Melendez-AlafortLaura Melendez-Alafort
Laura Melendez-Alafort
JRJeannette Rodríguez-Cortés
Jeannette Rodríguez-Cortés
Guillermina Ferro-FloresGuillermina Ferro-Flores
Guillermina Ferro-Flores
CMConsuelo Arteaga De Murphy
Consuelo Arteaga De Murphy
RHRuth Herrera-Rodríguez
Ruth Herrera-Rodríguez
CMCarlos Martínez-Duncker
Carlos Martínez-Duncker

1 December 2019 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
BGBrenda Gibbens-Bandala
Brenda Gibbens-Bandala
EMEnrique Morales-Avila
Enrique Morales-Avila
Guillermina Ferro-FloresGuillermina Ferro-Flores
Guillermina Ferro-Flores
CSClara Leticia Santos-Cuevas
Clara Leticia Santos-Cuevas
Laura Melendez-AlafortLaura Melendez-Alafort
Laura Melendez-Alafort
Blanca Ocampo-GarcíaBlanca Ocampo-García
Blanca Ocampo-García

1 September 2018 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
Petra MartiniPetra Martini
Petra Martini
Alessandra BoschiAlessandra Boschi
Alessandra Boschi
GCGianfranco Cicoria
Gianfranco Cicoria
FZFederico Zagni
Federico Zagni
ACAndrea Corazza
Andrea Corazza
Adriano DuattiAdriano Duatti
Adriano Duatti

1 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
DBDiana Sarahí Trujillo Benítez
Diana Sarahí Trujillo Benítez
MLMyrna Alejandra Luna-Gutiérrez
Myrna Alejandra Luna-Gutiérrez
Guillermina Ferro-FloresGuillermina Ferro-Flores
Guillermina Ferro-Flores
Blanca Ocampo-GarcíaBlanca Ocampo-García
Blanca Ocampo-García
CSClara Leticia Santos-Cuevas
Clara Leticia Santos-Cuevas
Laura Melendez-AlafortLaura Melendez-Alafort
Laura Melendez-Alafort
Fibroblast activation protein (FAP) is expressed in the microenvironment of most human epithelial tumors. 68Ga-labeled FAP inhibitors based on the cyanopyrrolidine structure (FAPI) are currently used for the detection of the tumor microenvironment by PET imaging. This research aimed to design, synthesize and preclinically evaluate a new FAP inhibitor radiopharmaceutical based on the 99mTc-((R)-1-((6-hydrazinylnicotinoyl)-D-alanyl) pyrrolidin-2-yl) boronic acid (99mTc-iFAP) structure for SPECT imaging. Molecular docking for affinity calculations was performed using the AutoDock software. The chemical synthesis was based on a series of coupling reactions of 6-hidrazinylnicotinic acid (HYNIC) and D-alanine to a boronic acid derivative. The iFAP was prepared as a lyophilized formulation based on EDDA/SnCl2 for labeling with 99mTc. The radiochemical purity (R.P.) was verified via ITLC-SG and reversed-phase radio-HPLC. The stability in human serum was evaluated by size-exclusion HPLC. In vitro cell uptake was assessed using N30 stromal endometrial cells (FAP positive) and human fibroblasts (FAP negative). Biodistribution and tumor uptake were determined in Hep-G2 tumor-bearing nude mice, from which images were acquired using a micro-SPECT/CT. The iFAP ligand (Ki = 0.536 nm, AutoDock affinity), characterized by UV-Vis, FT-IR, 1H–NMR and UPLC-mass spectroscopies, was synthesized with a chemical purity of 92%. The 99mTc-iFAP was obtained with a R.P. >98%. In vitro and in vivo studies indicated high radiotracer stability in human serum (>95% at 24 h), specific recognition for FAP, high tumor uptake (7.05 ± 1.13% ID/g at 30 min) and fast kidney elimination. The results found in this research justify additional dosimetric and clinical studies to establish the sensitivity and specificity of the 99mTc-iFAP.